Progress in Neurotherapeutics and Neuropsychopharmacology: Volume 3, 2008

Hardcover (Print)
Buy New
Buy New from
Used and New from Other Sellers
Used and New from Other Sellers
from $20.53
Usually ships in 1-2 business days
(Save 90%)
Other sellers (Hardcover)
  • All (8) from $20.53   
  • New (5) from $155.23   
  • Used (3) from $20.53   


Published annually, volumes in this series provide readers with updates of recent clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology.

Read More Show Less

Editorial Reviews

Doody's Review Service
Reviewer: Raj Tummala, MD (Wyeth Pharmaceuticals)
Description: This is an annual update of recent clinical trials and advances in the management of neurologic and neuropsychiatric disorders.
Purpose: The purpose is to provide a comprehensive review of the latest advances in clinical trials of neurologic and psychiatric disorders.
Audience: This is primarily targeted at neurologists, psychiatrists, drug developers, translational scientists, and anyone involved in research in the neurosciences.
Features: This volume focuses on both psychopharmacological management of neuropsychiatric disorders and nondrug treatments. All of the articles are authored by experts in the respective areas and are chosen by the editorial board. This edition captures advances in migraine, Parkinson disease, stroke, epilepsy, multiple sclerosis, Alzheimer's disease, traumatic brain injury, depression, and schizophrenia. It also covers the influence of these clinical trial results on practice guidelines and advances in trial methodologies. The topics are presented in a general consistent format that describes the trial methodology, outcome measures, and efficacy and safety results. Interesting in each chapter is the translation of the results to clinical practice and their impact on evidence-based medicine. The authors also discuss the unique aspects of the trial and the trial methodologies and their regulatory implications. Information is augmented with tables, graphs, and charts. Each chapter has an extensive reference section.
Assessment: The third edition captures the important progress and advances over the last year in neurological and psychiatric disorders. This is a nice series for any neuroscience researcher interested in clinical trial updates.
From the Publisher
'Of interest to adult neurologists and psychiatrists.' Pediatric Endocrinology Reviews
Read More Show Less

Product Details

  • ISBN-13: 9780521862554
  • Publisher: Cambridge University Press
  • Publication date: 5/7/2008
  • Pages: 312
  • Product dimensions: 6.85 (w) x 9.72 (h) x 0.71 (d)

Meet the Author

Jeffrey Cummings is Director of the Deane F. Johnson Center for Neurotherapeutics at UCLA and Director of the UCLA Alzheimer's Disease Center.

Read More Show Less

Table of Contents

Contributors; 1. Progress in neurotherapeutics and neuropsychopharmacology Jeffrey L. Cummings; 2. Trifusal versus aspirin for the prevention of stroke Antonio Culebras, Javier Borja and Julián García-Rafanell; 3. The Argatroban and tPA stroke study Andrew D. Barreto and James C. Grotta; 4. Use of Selegiline as monotherapy and in combination with Levodopa in the management of Parkinson's disease: perspectives from the MONOCOMB study Sven E. Pålhagen and Esa Heinonen; 5. Ropinirole 24-h prolonged release in advanced Parkinson's disease: review of a randomised, double-blind, placebo-controlled study (EASE PD - adjunct study) Kelly E. Lyons and Rajesh Pahwa; 6. Insulin resistance and Alzheimer's disease: pathophysiology and treatment G. Stennis Watson and Suzanne Craft; 7. Targeting Amyloid with Tramiprosate in patients with mild-to-moderate Alzheimer's disease P. S. Aisen, R. Briand, D. Saumier, J. Laurin, A. Duong and D. Garceau; 8. Intranasal Zolmitriptan is effective and well-tolerated in acute cluster headache: a randomized placebo-controlled double-blind crossover study E. Cittadini and P. J. Goadsby; 9. Optimal dosing of immunomodulating drugs: a dose-comparison study of GA in RRMS Daniel Wynn, Catherine Meyer, Neil Allen and Dennis O'Brien; 10. Tetrathiomolybdate versus Trientine in the initial treatment of neurologic Wilson's disease George J. Brewer, Fred Askari, Matthew T. Lorincz, Martha Carlson, Michael Schilsky, Karen J. Kluin, Peter Hedera, Paolo Moretti, John K. Fink, Roberta Tankanow, Robert B. Dick and Julia Sitterly; 11. Randomized clinical trials of Pregabalin for neuropathic pain: methods, results, and implications Robert H. Dworkin, Rajbala Thakur, Teresa Griesing, Uma Sharma and James P. Young; 12. Effect of Methylphenidate in patients with acute traumatic brain injury: a randomized clinical trial Hossein A. Khalili and Kamyar Keramatian; 13. Improvement in speeded cognitive processing after anti-epileptic drug withdrawal - a controlled study in mono-therapy patients Erik Hessen, Morten I. Lossius, Ivar Reinvang and Leif Gjerstad; 14. A randomized-controlled trial of bilateral rTMS for treatment-resistant depression Paul B. Fitzgerald; 15. Serotonin related genes affect antidepressant treatment in obsessive-compulsive disorder F. Van Nieuwerburgh, D. Deforce and D. A. J. P. Denys; 16. Night eating syndrome and results from the first placebo-controlled trial of treatment, with the SSRI medication, Sertraline: implications for clinical practice John P. O'Reardon Karen E. Groff, Albert J. Stunkard and Kelly C. Allison; 17. Modafinil: a candidate for pharmacotherapy of negative symptoms in schizophrenia John H. Peloian and Joseph M. Pierre; 18. New approaches to treatment of schizophrenia by enhancing N-methyl-D-aspartate neurotransmission Guochuan Emil Tsai; Subject index; Author index.

Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star


4 Star


3 Star


2 Star


1 Star


Your Rating:

Your Name: Create a Pen Name or

Barnes & Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation


  • - By submitting a review, you grant to Barnes & and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Terms of Use.
  • - Barnes & reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)